The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke.

IF 1.4 Q4 CLINICAL NEUROLOGY Dementia and Geriatric Cognitive Disorders Extra Pub Date : 2021-06-10 eCollection Date: 2021-05-01 DOI:10.1159/000516074

Jong-Hoon Lee, Chul Joong Lee, Jungwuk Park, So Jeong Lee, Su-Hee Choi

{"title":"The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke.","authors":"Jong-Hoon Lee, Chul Joong Lee, Jungwuk Park, So Jeong Lee, Su-Hee Choi","doi":"10.1159/000516074","DOIUrl":null,"url":null,"abstract":"Aim/background: This review investigated a patient with Alzheimer's disease (AD) treated with 4,4'-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor.Methods: We monitored AD's progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct.Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24-55 h in the Seoul Study cohort.","PeriodicalId":38017,"journal":{"name":"Dementia and Geriatric Cognitive Disorders Extra","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000516074","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders Extra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000516074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 15

Abstract

Aim/background: This review investigated a patient with Alzheimer's disease (AD) treated with 4,4'-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor.

Methods: We monitored AD's progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state.

Results: By introducing (D), AD's progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct.

Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24-55 h in the Seoul Study cohort.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿尔茨海默病和脑卒中中的神经炎性体。

目的/背景:本综述研究了用4,4′-二氨基二苯砜(DDS)作为神经炎性小体竞争对手治疗阿尔茨海默病(AD)患者。方法:我们使用一种新的生物标志物，通过数值临床分期(NCS)监测AD的进展。NCS是通过AD症状和抗AD (AAD)药物(D)引起的神经精神(NP)症状的存在作为生物标志物来确定的。我们还监测了无摄入紧急状态下脑卒中DDS的功能。结果:通过引入(D)，通过NCS分期监测AD的进展。确定了AAD的副作用和神经精神症状。AAD引起的NCS 6型脑卒中患者停用DDS，并迅速发展为脑梗死。结论:AAD偶尔会加重AD和脑卒中。DDS可减轻轻度认知障碍(MCI)、早期AD和中风。我们临床证实了DDS作为脑卒中后神经炎性小体竞争者的作用。在首尔研究队列中，DDS可在24-55小时内保存神经元存活。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dementia and Geriatric Cognitive Disorders Extra Medicine-Psychiatry and Mental Health

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： This open access and online-only journal publishes original articles covering the entire spectrum of cognitive dysfunction such as Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field. Dementia and Geriatric Cognitive Disorders Extra provides additional contents based on reviewed and accepted submissions to the main journal Dementia and Geriatric Cognitive Disorders Extra .